BridgeBio Pharma, Inc. Common Stock (BBIO) Stock Price
BBIOStock
$76.60+45.71%52W
Market Cap$14.97B
P/E—
PEG Ratio—
Div yield—
Beta0.94
BBIO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)0.21%
Price vs S&P 500 (4W)-5.74%
VGM Score56.19
BBIO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.58 | -$0.78 | -33.87%(-$0.20) | |
| Q1 2026 | -$0.62 | -$0.84 | -36.22%(-$0.22) | |
| Q4 2025 | -$0.62 | -$0.94 | -50.63%(-$0.32) | |
| Q3 2025 | -$0.89 | -$0.95 | -6.71%(-$0.06) | |
| Q2 2025 | -$0.60 | -$0.95 | -57.12%(-$0.35) |
BBIO Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.27
4.21
4.20
4.11
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BBIOBridgeBio Pharma, Inc. Common Stock | F | A | B | $76.60 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About BridgeBio Pharma, Inc. Common Stock
BridgeBio Pharma develops treatments for genetic diseases through a late-stage pipeline of four programs targeting Mendelian disorders, oncology, and gene therapy. Its lead candidate, Attruby (acoramidis), is an orally administered small molecule designed to stabilize transthyretin for the treatment of transthyretin amyloid cardiomyopathy.